Side-by-side · Research reference

CartalaxvsCrystagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BAnimal-MechanisticHUMAN-REVIEWED12/40 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

01Mechanism of Action

Parameter

Cartalax

Crystagen

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

B-lymphocytes in splenic tissueСhervyakova 2014

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

B-cell activation → Immune modulation during agingСhervyakova 2014

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Feedback intact?

—

Unknown — bioregulator mechanism not fully characterized

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

Crystagen

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Animal / mechanistic

Standard dose

—

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

Route

—

Subcutaneous (presumed from bioregulator class)

Frequency

—

Unknown — bioregulator protocols variable

Duration

—

Unknown — chronic administration presumed in animal models

Half-life

—

Not reported

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Crystagen

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Crystagen

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

Absent — no controlled human trials identified

Published adverse events

—

None reported in available animal literature

Autoimmune considerations

—

Theoretical concern with B-cell modulators in predisposed individuals

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Crystagen

·Active autoimmune disease (theoretical)

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

05Administration Protocol

Parameter

Cartalax

Crystagen

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

4. Storage

—

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

06Stack Synergy

Cartalax

— no documented stacks

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014